Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
KOSDAQ - Delayed Quote KRW

Daesung Microbiological Labs. Co., Ltd. (036480.KQ)

Compare
8,370.00
-90.00
(-1.06%)
At close: April 4 at 3:30:30 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
23,803,929.08
23,803,929.08
25,562,323.13
25,500,064.65
23,997,251.52
Cost of Revenue
19,752,419.85
19,752,419.85
20,712,863.89
20,706,504.90
18,259,631.76
Gross Profit
4,051,509.23
4,051,509.23
4,849,459.24
4,793,559.75
5,737,619.76
Operating Expense
5,603,231
5,603,231
5,538,470
5,121,082
5,400,514
Operating Income
-1,551,721.77
-1,551,721.77
-689,010.76
-327,522.25
337,105.76
Net Non Operating Interest Income Expense
-549,610.78
-549,610.78
-518,242.95
-298,699.67
-158,797.16
Pretax Income
-1,571,040.13
-1,571,040.13
-1,081,728.27
2,260,571.04
842,866.86
Tax Provision
198,322.59
198,322.59
-402,052.75
557,381.17
-23,049.65
Net Income Common Stockholders
-1,769,362.73
-1,769,362.73
-679,675.51
1,703,189.87
865,916.51
Basic EPS
-466.00
--
-179.00
448.00
227.00
Diluted EPS
-466.00
--
-179.00
448.00
227.00
Basic Average Shares
3,796.92
--
3,797.07
3,801.76
3,814.61
Diluted Average Shares
3,796.92
--
3,797.07
3,801.76
3,814.61
Total Operating Income as Reported
-1,551,719.61
-1,551,719.61
-689,011.92
-327,522.92
337,105.72
Total Expenses
25,355,650.85
25,355,650.85
26,251,333.89
25,827,586.90
23,660,145.76
Net Income from Continuing & Discontinued Operation
-1,769,362.73
-1,769,362.73
-679,675.51
1,703,189.87
865,916.51
Normalized Income
-1,777,922.61
-1,777,922.61
-676,432.10
38,644.39
865,618.01
Interest Income
296,552
296,552
374,423
213,883
119,029
Interest Expense
846,163
846,163
892,666
512,582
277,530
Net Interest Income
-549,610.78
-549,610.78
-518,242.95
-298,699.67
-158,797.16
EBIT
-724,877.13
-724,877.13
-189,062.27
2,773,153.04
1,120,396.86
EBITDA
990,007.87
990,007.87
2,672,997.73
5,478,905.04
3,658,594.86
Reconciled Cost of Revenue
19,752,419.85
19,752,419.85
20,712,863.89
20,706,504.90
18,259,631.76
Reconciled Depreciation
1,714,885
1,714,885
2,862,060
2,705,752
2,538,198
Net Income from Continuing Operation Net Minority Interest
-1,769,362.73
-1,769,362.73
-679,675.51
1,703,189.87
865,916.51
Total Unusual Items Excluding Goodwill
11,263
11,263
-5,162
2,209,280
398
Total Unusual Items
11,263
11,263
-5,162
2,209,280
398
Normalized EBITDA
978,744.87
978,744.87
2,678,159.73
3,269,625.04
3,658,196.86
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
2,703.12
2,703.12
-1,918.59
544,734.52
99.50
12/31/2021 - 9/14/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

WXIBF WuXi Biologics (Cayman) Inc.
3.7000
0.00%
 
207940.KS Samsung Biologics Co.,Ltd.
1,069,000.00
-3.95%
 
WXXWY WuXi Biologics (Cayman) Inc.
5.76
+1.41%
 
2269.HK WuXi Biologics (Cayman) Inc.
24.850
-5.33%
 
BNTX BioNTech SE
88.05
-4.30%
 
PCVX Vaxcyte, Inc.
31.60
+3.40%
 
VRTX Vertex Pharmaceuticals Incorporated
474.62
-1.94%
 
NVAX Novavax, Inc.
6.24
+11.43%
 
MRNA Moderna, Inc.
25.11
-2.41%